

---

**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**SCHEDULE 13D**

Under the Securities Exchange Act of 1934

**(Amendment No. 2)\***

**WEREWOLF THERAPEUTICS, INC.**

---

**(Name of Issuer)**

**Common Stock**

---

**(Title of Class of Securities)**

**95075A107**

---

**(CUSIP Number)**

**Ansbert Gadicke**  
**c/o MPM BioImpact LLC, 339 Boylston Street, Suite 1100**  
**Boston, MA, 02116**  
**617-425-9200**

---

**(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)**

**11/13/2025**

---

**(Date of Event Which Requires Filing of This Statement)**

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

**SCHEDULE 13D**

**CUSIP No. 95075A107**

Name of reporting person

1

MPM BioVentures 2014, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)  
 (b)

3 SEC use only  
Source of funds (See Instructions)

4 WC  
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5   
Citizenship or place of organization

6 DELAWARE  
Sole Voting Power

7 2,377,515.00  
Number of Shares Beneficially Owned by Each Reporting Person With: Shared Voting Power

8 0.00  
Sole Dispositive Power

9 2,377,515.00  
Shared Dispositive Power

10 0.00  
Aggregate amount beneficially owned by each reporting person

11 2,377,515.00  
Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12   
Percent of class represented by amount in Row (11)

13 4.9 %  
Type of Reporting Person (See Instructions)

14 PN

## SCHEDULE 13D

**CUSIP No.** 95075A107

1 Name of reporting person  
MPM BioVentures 2014 (B), L.P.  
Check the appropriate box if a member of a Group (See Instructions)

2  (a)  
 (b)

3 SEC use only  
Source of funds (See Instructions)

4 WC  
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5   
Citizenship or place of organization

6 DELAWARE  
Sole Voting Power

7

Shares Beneficially Owned by Each Reporting Person With: 158,577.00  
 Shared Voting Power  
 8  
 0.00  
 Sole Dispositive Power  
 9  
 158,577.00  
 Shared Dispositive Power  
 10  
 0.00  
 Aggregate amount beneficially owned by each reporting person  
 11  
 158,577.00  
 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)  
 12  
  
 Percent of class represented by amount in Row (11)  
 13  
 0.3 %  
 Type of Reporting Person (See Instructions)  
 14  
 PN

## SCHEDULE 13D

**CUSIP No.** 95075A107

1 Name of reporting person  
 MPM Asset Management Investors BV2014 LLC  
 Check the appropriate box if a member of a Group (See Instructions)  
 2  
 (a)  
 (b)  
 3 SEC use only  
 Source of funds (See Instructions)  
 4  
 WC  
 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)  
 5  
  
 Citizenship or place of organization  
 6  
 DELAWARE  
 Sole Voting Power  
 7  
 Number of Shares Beneficially Owned by Each Reporting Person With: 81,832.00  
 Shared Voting Power  
 8  
 0.00  
 Sole Dispositive Power  
 9  
 81,832.00  
 Shared Dispositive Power  
 10  
 0.00  
 11 Aggregate amount beneficially owned by each reporting person

81,832.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13

0.2 %

Type of Reporting Person (See Instructions)

14

OO

### SCHEDULE 13D

**CUSIP No.** 95075A107

Name of reporting person

1

UBS Oncology Impact Fund L.P.

Check the appropriate box if a member of a Group (See Instructions)

2

(a)

(b)

3

SEC use only

Source of funds (See Instructions)

4

WC

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

Citizenship or place of organization

6

CAYMAN ISLANDS

Sole Voting Power

7

1,965,659.00

Number of Shares

Shared Voting Power

Beneficially 8

0.00

Owned by

Each

Sole Dispositive Power

Reporting 9

1,965,659.00

Person

With:

Shared Dispositive Power

10

0.00

Aggregate amount beneficially owned by each reporting person

11

1,965,659.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13

4.0 %

Type of Reporting Person (See Instructions)

14

PN

# SCHEDULE 13D

**CUSIP No.** 95075A107

1 Name of reporting person  
MPM BioVentures 2014 GP LLC  
Check the appropriate box if a member of a Group (See Instructions)

2  (a)  
 (b)

3 SEC use only  
Source of funds (See Instructions)

4 WC  
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5   
Citizenship or place of organization

6 DELAWARE

7 Sole Voting Power  
0.00

Number of  
Shares  
Beneficially  
Owned by  
Each  
Reporting  
Person  
With:

8 Shared Voting Power  
2,536,092.00

9 Sole Dispositive Power  
0.00

10 Shared Dispositive Power  
2,536,092.00

11 Aggregate amount beneficially owned by each reporting person  
2,536,092.00  
Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12   
Percent of class represented by amount in Row (11)

13 5.2 %  
Type of Reporting Person (See Instructions)

14 OO

# SCHEDULE 13D

**CUSIP No.** 95075A107

1 Name of reporting person  
MPM BioVentures 2014 LLC  
Check the appropriate box if a member of a Group (See Instructions)

2  (a)  
 (b)

3 SEC use only  
Source of funds (See Instructions)

4 WC  
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5   
Citizenship or place of organization

6 DELAWARE

7 Sole Voting Power

Number of Shares Beneficially Owned by Each Reporting Person With: 8 0.00  
Shared Voting Power

9 2,617,924.00  
Sole Dispositive Power

10 0.00  
Shared Dispositive Power

11 2,617,924.00  
Aggregate amount beneficially owned by each reporting person

12 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13   
Percent of class represented by amount in Row (11)

14 5.4 %  
Type of Reporting Person (See Instructions)

OO

## SCHEDULE 13D

**CUSIP No.** 95075A107

1 Name of reporting person  
Oncology Impact Fund (Cayman) Management L.P.  
Check the appropriate box if a member of a Group (See Instructions)

2  (a)  
 (b)

3 SEC use only  
Source of funds (See Instructions)

4 WC  
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5   
Citizenship or place of organization

6 CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With: 7 Sole Voting Power  
0.00

Owned by Each Reporting Person With:	8	Shared Voting Power
		1,965,659.00
		Sole Dispositive Power
	9	0.00
		Shared Dispositive Power
	10	1,965,659.00
11	Aggregate amount beneficially owned by each reporting person	
		1,965,659.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)	
		<input type="checkbox"/>
13	Percent of class represented by amount in Row (11)	
		4.0 %
14	Type of Reporting Person (See Instructions)	
		PN

## SCHEDULE 13D

**CUSIP No.** 95075A107

1	Name of reporting person	
	MPM BioImpact LLC	
	Check the appropriate box if a member of a Group (See Instructions)	
2	<input type="checkbox"/>	(a)
	<input checked="" type="checkbox"/>	(b)
3	SEC use only	
4	Source of funds (See Instructions)	
	WC	
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)	
	<input type="checkbox"/>	
6	Citizenship or place of organization	
	DELAWARE	
		Sole Voting Power
	7	0.00
		Shared Voting Power
Number of Shares Beneficially Owned by Each Reporting Person With:	8	1,965,659.00
		Sole Dispositive Power
	9	0.00
		Shared Dispositive Power
	10	1,965,659.00
11	Aggregate amount beneficially owned by each reporting person	
		1,965,659.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)	

Percent of class represented by amount in Row (11)  
13 4.0 %  
Type of Reporting Person (See Instructions)  
14 OO

## SCHEDULE 13D

**CUSIP No.** 95075A107

1 Name of reporting person  
ANSBERT GADICKE  
Check the appropriate box if a member of a Group (See Instructions)  
2  (a)  
 (b)  
3 SEC use only  
Source of funds (See Instructions)  
4 WC  
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)  
5   
Citizenship or place of organization  
6 UNITED STATES  
Sole Voting Power  
7 0.00  
Number of Shares Beneficially Owned by Each Reporting Person With:  
8 Shared Voting Power  
5,481,539.00  
Sole Dispositive Power  
9 0.00  
Shared Dispositive Power  
10 5,481,539.00  
Aggregate amount beneficially owned by each reporting person  
11 5,481,539.00  
Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)  
12   
Percent of class represented by amount in Row (11)  
13 11.3 %  
Type of Reporting Person (See Instructions)  
14 IN

## SCHEDULE 13D

1 Name of reporting person  
LUKE EVNIN  
Check the appropriate box if a member of a Group (See Instructions)

2  (a)  
 (b)

3 SEC use only  
Source of funds (See Instructions)

4 WC  
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5   
Citizenship or place of organization

6 UNITED STATES  
Sole Voting Power

7 0.00  
Number of Shares Beneficially Owned by Each Reporting Person With:  
Shared Voting Power

8 3,515,880.00  
Sole Dispositive Power

9 0.00  
Shared Dispositive Power

10 3,515,880.00  
Aggregate amount beneficially owned by each reporting person

11 3,515,880.00  
Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12   
Percent of class represented by amount in Row (11)

13 7.2 %  
Type of Reporting Person (See Instructions)

14 IN

SCHEDULE 13D

1 Name of reporting person  
Todd Foley  
Check the appropriate box if a member of a Group (See Instructions)

2  (a)  
 (b)

3 SEC use only  
Source of funds (See Instructions)

4

WC

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

Citizenship or place of organization

6

UNITED STATES

Sole Voting Power

7

0.00

Number of  
Shares

Shared Voting Power

Beneficially

8

Owned by

2,617,924.00

Each

Sole Dispositive Power

Reporting

9

Person

0.00

With:

Shared Dispositive Power

10

2,617,924.00

Aggregate amount beneficially owned by each reporting person

11

2,617,924.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13

5.4 %

Type of Reporting Person (See Instructions)

14

IN

## SCHEDULE 13D

**CUSIP No.** 95075A107

Name of reporting person

1

MPM ASSET MANAGEMENT LLC

Check the appropriate box if a member of a Group (See Instructions)

2

(a)

(b)

3

SEC use only

Source of funds (See Instructions)

4

WC

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

Citizenship or place of organization

6

DELAWARE

Sole Voting Power

7

376,471.00

Number of  
Shares

Beneficially

Owned by

8

Shared Voting Power

Each

Reporting Person	0.00
With:	Sole Dispositive Power
	9
	376,471.00
	Shared Dispositive Power
	10
	0.00
	Aggregate amount beneficially owned by each reporting person
11	376,471.00
	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
12	<input type="checkbox"/>
	Percent of class represented by amount in Row (11)
13	0.8 %
	Type of Reporting Person (See Instructions)
14	OO

## SCHEDULE 13D

**CUSIP No.** 95075A107

1	Name of reporting person
	MPM ONCOLOGY INNOVATIONS FUND LP
	Check the appropriate box if a member of a Group (See Instructions)
2	<input type="checkbox"/> (a)
	<input checked="" type="checkbox"/> (b)
3	SEC use only
	Source of funds (See Instructions)
4	WC
	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
5	<input type="checkbox"/>
	Citizenship or place of organization
6	DELAWARE
	Sole Voting Power
	7
	521,485.00
Number of Shares Beneficially Owned by Each Reporting Person	8
With:	Shared Voting Power
	0.00
	Sole Dispositive Power
	9
	521,485.00
	Shared Dispositive Power
	10
	0.00
	Aggregate amount beneficially owned by each reporting person
11	521,485.00
	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
12	<input type="checkbox"/>

13 Percent of class represented by amount in Row (11)

1.1 %

Type of Reporting Person (See Instructions)

14

PN

## SCHEDULE 13D

**CUSIP No.** 95075A107

Name of reporting person

1

MPM Oncology Innovations Fund GP LLC

Check the appropriate box if a member of a Group (See Instructions)

2

(a)

(b)

3

SEC use only

Source of funds (See Instructions)

4

WC

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

Citizenship or place of organization

6

DELAWARE

Sole Voting Power

7

0.00

Number of  
Shares

Shared Voting Power

Beneficially 8

Owned by

521,485.00

Each

Sole Dispositive Power

Reporting 9

Person

0.00

With:

Shared Dispositive Power

10

521,485.00

Aggregate amount beneficially owned by each reporting person

11

521,485.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13

1.1 %

Type of Reporting Person (See Instructions)

14

OO

## SCHEDULE 13D

Item 1. Security and Issuer



BioVentures 2014 GP LLC, the General Partner of  
MPM BioVentures 2014, L.P.

Date: 11/17/2025

MPM BioVentures 2014 (B), L.P.

Signature: /s/ Ansbert Gadicke

Name/Title: Managing Director of MPM BioVentures 2014  
LLC, Managing Member of MPM BioVentures  
2014 GP LLC, the General Partner of MPM  
BioVentures 2014 (B), L.P.

Date: 11/17/2025

MPM Asset Management Investors BV2014 LLC

Signature: /s/ Ansbert Gadicke

Name/Title: Managing Director of MPM BioVentures 2014  
LLC, the manager of MPM Asset Management  
Investors BV2014 LLC

Date: 11/17/2025

UBS Oncology Impact Fund L.P.

Signature: /s/ Ansbert Gadicke

Name/Title: Managing Partner of MPM BioImpact LLC, the  
GP of Oncology Impact Fund (Cayman)  
Management L.P., the GP of UBS Oncology  
Impact Fund L.P.

Date: 11/17/2025

MPM BioVentures 2014 GP LLC

Signature: /s/ Ansbert Gadicke

Name/Title: Managing Director of MPM BioVentures 2014  
LLC, the Managing Member of MPM  
BioVentures 2014 GP LLC

Date: 11/17/2025

MPM BioVentures 2014 LLC

Signature: /s/ Ansbert Gadicke

Name/Title: Managing Director

Date: 11/17/2025

Oncology Impact Fund (Cayman) Management L.P.

Signature: /s/ Ansbert Gadicke

Name/Title: Managing Partner of MPM BioImpact LLC, the  
General Partner of Oncology Impact Fund  
(Cayman) Management L.P.

Date: 11/17/2025

MPM BioImpact LLC

Signature: /s/ Ansbert Gadicke

Name/Title: Managing Partner

Date: 11/17/2025

ANSBERT GADICKE

Signature: /s/ Ansbert Gadicke

Name/Title: Ansbert Gadicke

Date: 11/17/2025

LUKE EVNIN

Signature: /s/ Luke Evnin

Name/Title: Luke Evnin

Date: 11/17/2025

Todd Foley

Signature: /s/ Todd Foley

Name/Title: Todd Foley

Date: 11/17/2025

MPM ASSET MANAGEMENT LLC

Signature: /s/ Ansbert Gadicke

Name/Title: Member

Date: 11/17/2025

MPM ONCOLOGY INNOVATIONS FUND LP

Signature: /s/ Ansbert Gadicke

Manager of MPM Oncology Innovations Fund GP  
Name/Title: LLC, the General Partner of MPM Oncology  
Innovations Fund, L.P.

Date: 11/17/2025

MPM Oncology Innovations Fund GP LLC

Signature: /s/ Ansbert Gadicke

Name/Title: Manager

Date: 11/17/2025

**Joint Filing Statement**

I, the undersigned, hereby express my agreement that the attached Schedule 13D (and any amendments thereto) relating to the beneficial ownership by the undersigned of the equity securities of Werewolf Therapeutics, Inc. is filed on behalf of each of the undersigned.

Date: November 17, 2025

**MPM BioVentures 2014, L.P.**

By: MPM BioVentures 2014 GP LLC,  
its General Partner

By: MPM BioVentures 2014 LLC,  
Its Managing Member

By: /s/ Ansbert Gadicke  
Name: Ansbert Gadicke  
Title: Managing Director

**MPM BioVentures 2014 (B), L.P.**

By: MPM BioVentures 2014 GP LLC,  
its General Partner

By: MPM BioVentures 2014 LLC,  
Its Managing Member

By: /s/ Ansbert Gadicke  
Name: Ansbert Gadicke  
Title: Managing Director

**MPM Asset Management Investors BV 2014 LLC**

By: MPM BioVentures 2014 LLC  
Its: Manager

By: /s/ Ansbert Gadicke  
Name: Ansbert Gadicke  
Title: Managing Director

**MPM BioVentures 2014 GP, LLC**

By: MPM BioVentures 2014 LLC,  
Its Managing Member

By: /s/ Ansbert Gadicke  
Name: Ansbert Gadicke  
Title: Managing Director

---

**MPM BioVentures 2014 LLC**

By: /s/ Ansbert Gadicke  
Name: Ansbert Gadicke  
Title: Managing Director

**MPM Asset Management LLC**

By: /s/ Ansbert Gadicke  
Name: Ansbert Gadicke  
Title: Member

**MPM Oncology Innovations Fund LP**

By: MPM Oncology Innovations Fund GP LLC  
its General Partner

By: /s/ Ansbert Gadicke  
Name: Ansbert Gadicke  
Title: Manager

**MPM Oncology Innovations Fund GP LLC**

By: /s/ Ansbert Gadicke  
Name: Ansbert Gadicke  
Title: Manager

**UBS Oncology Impact Fund, L.P.**

By: Oncology Impact Fund (Cayman) Management L.P.,  
its General Partner

By: MPM BioImpact LLC,  
Its General Partner

By: /s/ Ansbert Gadicke  
Name: Ansbert Gadicke  
Title: Managing Partner

---

**Oncology Impact Fund (Cayman) Management L.P.**

By: MPM BioImpact LLC,  
Its General Partner

By: /s/ Ansbert Gadicke  
Name: Ansbert Gadicke  
Title: Managing Partner

**MPM BioImpact LLC**

By: /s/ Ansbert Gadicke  
Name: Ansbert Gadicke  
Title: Managing Partner

By: /s/ Todd Foley  
Name: Todd Foley

By: /s/ Luke Evin  
Name: Luke Evin

By: /s/ Ansbert Gadicke  
Name: Ansbert Gadicke

---